Which Current and Novel Diagnostic Avenues for Bacterial Respiratory Diseases?

Rytter, Héloïse; Jamet, Anne; Coureuil, Mathieu; Charbit, Alain; Ramond, Elodie

doi:10.3389/fmicb.2020.616971

Cited by 13 publications

(19 citation statements)

References 100 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecular techniques are also becoming available at point-of-care (POC) or near-POC as different portable molecular diagnostic instruments are being developed [49]. These syndromic multiplex panels can be used to detect the pathogen DNA or RNA most commonly associated with RTI, including viruses and bacterial atypical pathogens [50][51][52][53][54]. Advantages include decreased time to detection, the possibility of quantification and detection of resistance and virulence genes.…”

Section: Appropriate Sample and Methodologymentioning

confidence: 99%

Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms?

Stojanović

Gonçalves-Carvalho²,

Marín³

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

Respiratory tract infections (RTI) are one of the commonest reasons for seeking healthcare, but are amongst the most challenging diseases in terms of clinical decision making. Proper and timely diagnosis is critical in order to optimize management and prevent further emergence of antimicrobial resistance by misuse, or overuse of antibiotics. Diagnostic tools for RTI include those involving syndromic and etiological diagnosis: from clinical and radiological features to laboratory methods targeting both pathogen detection and host biomarkers, as well as their combinations in terms of clinical algorithms. They also include tools for predicting severity and monitoring treatment response. Unprecedented milestones have been achieved in the context of the COVID-19 pandemic, involving the most recent applications of diagnostic technologies both at genotypic and phenotypic level, which have changed paradigms in infectious respiratory diseases in terms of why, how and where diagnostics are performed. The aim of this review is to discuss advances in diagnostic tools that impact clinical decision making, surveillance and follow-up of RTI and tuberculosis. If properly harnessed, recent advances in diagnostic technologies, including omics and digital transformation emerge as an unprecedented opportunity to tackle ongoing and future epidemics while handling antimicrobial resistance from a One Health perspective.

show abstract

Section: Appropriate Sample and Methodologymentioning

confidence: 99%

Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms?

Stojanović

Gonçalves-Carvalho²,

Marín³

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

show abstract

“…It does not require assumptions about the type of infection‐causing pathogen. 23 , 24 With mNGS, unculturable or difficult‐to‐cultivate microbial species, as well as unknown or rare microbial species can be identified in complex samples. 25 Moreover, mNGS offers the advantage of a short turnaround time and can be used for genus and species identification.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, the patient's BALF was tested immediately using mNGS and culture, and mucor mold was quickly found, which clarified the diagnosis and accelerated the treatment It does not require assumptions about the type of infection-causing pathogen. 23,24 With mNGS, unculturable or difficult-to-cultivate microbial species, as well as unknown or rare microbial species can be identified in complex samples. 25 Moreover, mNGS offers the advantage of a short turnaround time and can be used for genus and species identification.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple diagnostic methods for mucormycosis: A retrospective case series

Wang

Han

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Mucormycosis is a rare invasive fungal disease with high mortality. Early diagnosis and targeted drugs are crucial to improving clinical outcomes. Methods We searched the electronic hospital database of the First Affiliated Hospital of Zhejiang University School of Medicine for adult patients with mucormycosis between 2000 and 2021. Demographic, clinical, treatment, and outcome data were collected and compared with the data in the relevant literature. Results Eleven cases of mucormycosis—four of multisite infection, one of skin infection, five of lung infection, and one of gastrointestinal infection—were found and analyzed. The patients were diagnosed mainly based on pathological and histological findings, and three patients had metagenomic next‐generation sequencing findings. Delayed diagnosis (i.e., diagnosis >7 days after patient admission or >30 days after onset of symptoms) results in poor prognosis compared with early diagnosis. Conclusions Improving awareness and shortening diagnosis time may improve the prognosis of mucormycosis. If mucormycosis is suspected, appropriate samples should be collected as soon as possible and submitted for biopsy, culture, or mNGS to confirm the diagnosis.

show abstract

“…With regard to tropical disease diagnosis, RDT deployment must consider local epidemiological data in order to avoid unnecessary testing. For RTI diagnosis, several syndromic multiplex PCR panels that can differentiate relevant bacterial and viral pathogens and assess resistance markers are now available, with results typically available within a few hours [ 17 ]. Available data suggest that rapid identification of viral infections of the respiratory tract can reduce antibacterial use [ 8 , 18 , 19 ].…”

Section: Delphi Consensus Statementsmentioning

confidence: 99%

Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus

Apisarnthanarak

Kim

Moore

et al. 2021

Clinical Infectious Diseases

View full text Add to dashboard Cite

Rapid diagnostic tests (RDTs) facilitate fast and accurate identification of infectious disease microorganisms and are a valuable component of multimodal antimicrobial stewardship (AMS) programs, but are currently underutilized in Asia Pacific. An experienced group of infectious diseases clinicians, clinical microbiologists and a clinical pharmacist used a modified Delphi consensus approach to construct 10 statements aiming to optimize the utility and applicability of infection-related RDTs for AMS in the Asia Pacific region. They provide guidance on definition, types, optimal deployment, measuring effectiveness, and overcoming key challenges. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was applied to indicate the strength of the recommendation and the quality of the underlying evidence. Given the diversity of Asia Pacific, the trajectory of RDT development will vary widely; the collection of local data should be prioritized to allow realization and optimization of the full benefits of RDT in AMS.

show abstract

Which Current and Novel Diagnostic Avenues for Bacterial Respiratory Diseases?

Cited by 13 publications

References 100 publications

Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms?

Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms?

Multiple diagnostic methods for mucormycosis: A retrospective case series

Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus

Contact Info

Product

Resources

About